ArticleJournal of medical toxicology : official journal of the American College of Medical Toxicology2026
Octreotide Administration Methods in Sulfonylurea Poisoning: A Retrospective Chart Review.
Article in Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOctreotide is used to treat sulfonylurea induced hypoglycemia, but the effectiveness of intravenous bolus, intravenous infusion, and subcutaneous routes of octreotide administration has not been compared.
methodsThis is a multi-center, retrospective chart review of patients with suspected sulfonylurea induced hypoglycemia who received octreotide, comparing intravenous bolus, intravenous infusion, and/or subcutaneous routes of octreotide administration. The primary outcome was number of hypoglycemic events after octreotide initiation. Secondary outcomes included total octreotide dose, dextrose administered before and after first octreotide dose, and hospital length of stay.
resultsOf 29 included cases, the intravenous bolus group had 10 patients, intravenous infusion group had four patients, and the subcutaneous group had 15 patients. Median post-octreotide hypoglycemic events were zero, 1.5, and zero for bolus, infusion, and subcutaneous groups, respectively. Median total octreotide dose was 50 mcg [IQR: 49 - 100 mcg], 693 mcg [IQR: 402 - 939 mcg], and 100 mcg [IQR: 50 - 150 mcg] for bolus, infusion, and subcutaneous groups, respectively. The bolus (115 grams [41 - 152 grams]) and subcutaneous groups (80 grams [53 - 189 grams]) received less post-octreotide dextrose than the infusion group (256 grams [86 - 560 grams]). Median length was 40, 60, and 62 hours between the bolus, infusion, and subcutaneous groups, respectively.
conclusionThe infusion group had a higher incidence of hypoglycemia and received more post-octreotide dextrose than intravenous bolus or subcutaneous groups, despite a larger total octreotide dose. These findings suggest octreotide infusions may be inferior, but further studies are needed to determine the optimal octreotide administration route for sulfonylurea induced hypoglycemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.